Theliatinib (HMPL-309)
Modify Date: 2023-02-06 17:30:29
Theliatinib (HMPL-309) structure
|
Common Name | Theliatinib (HMPL-309) | ||
|---|---|---|---|---|
| CAS Number | 1353644-70-8 | Molecular Weight | 442.52 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C25H26N6O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Theliatinib (HMPL-309)Theliatinib (HMPL-309) is a potent, ATP-competitive and highly selective EGFR inhibitor, significantly inhibits phosphorylation of EGFR (p-EGFR) and its downstream targets, AKT and ERK (p-AKT and p-ERK), with anti-tumor activity. Theliatinib (HMPL-309) shows a Ki of 0.05 nM for wild type EGFR, and IC50s of 3 and 22 nM for EGFR and EGFR T790M/L858R mutant, respectively[1]. |
| Name | Theliatinib |
|---|---|
| Synonym | More Synonyms |
| Description | Theliatinib (HMPL-309) is a potent, ATP-competitive and highly selective EGFR inhibitor, significantly inhibits phosphorylation of EGFR (p-EGFR) and its downstream targets, AKT and ERK (p-AKT and p-ERK), with anti-tumor activity. Theliatinib (HMPL-309) shows a Ki of 0.05 nM for wild type EGFR, and IC50s of 3 and 22 nM for EGFR and EGFR T790M/L858R mutant, respectively[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 3 nM (EGFR), 22 nM (EGFR T790M/L858R)[1] Ki: 0.05 nM (EGFR)[1] |
| References |
| Molecular Formula | C25H26N6O2 |
|---|---|
| Molecular Weight | 442.52 |
| (3aR,6aR)-N-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yl)-1-methyl-hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide |
| HMPL-309 |